快讯热点！房市新政一个月：各地积极跟进 政策效应逐步显现

房市新政一个月：各地积极跟进 政策效应逐步显现

北京，2024年6月18日 - 5月17日，中国人民银行、国家金融监督管理总局等部门出台了一系列支持房地产的举措，被称为“517楼市新政”。一个月来，各地积极跟进，相关政策效应逐步显现，市场信心逐步回暖。

政策频出，释放积极信号

“517楼市新政”主要包括以下内容：

• 取消全国层面房贷利率下限
• 下调首付比例和公积金贷款利率
• 设立保障性住房再贷款

**各地结合自身实际，出台了一系列细化政策。**例如，上海、广州、深圳等一线城市下调了首套房首付比例；杭州、南京、苏州等二线城市放宽了限购政策；郑州、合肥、济南等三四线城市降低了公积金贷款利率。

市场反应积极，成交量有所回升

从各地的数据来看，“517楼市新政”对市场产生了积极影响。

• **新房市场：**据国家统计局数据，5月份，北京、上海、广州、深圳等一线城市新房价格环比下降，但降幅有所收窄；二线城市新房价格总体平稳；三四线城市新房价格小幅回升。
• **二手房市场：**据贝壳研究院数据，5月份，重点50城二手房价格环比下跌，但降幅有所收窄。

业内人士认为，“517楼市新政”及其后续政策落地，有利于促进房地产市场平稳健康发展。

房企加快复工复产，投资信心有所增强

“517楼市新政”也提振了房企的信心。

• 据克而瑞数据，5月份，百强房企销售额同比下降28.9%，但降幅较4月份有所收窄。
• 据中指研究院数据，5月份，重点100城房地产企业拿地总面积同比下降43.1%，但降幅较4月份有所收窄。

**业内人士表示，**随着“517楼市新政”**政策效果的逐步显现，房企投资信心将进一步增强，房地产投资将有所回升。

专家建言，长效机制需加快建立

**尽管“517楼市新政”**取得了初步成效，但房地产市场仍处于调整期。

• **专家建议，**应加快建立和完善住房长效机制，促进房地产市场平稳健康发展。
• **具体而言，应加大对保障性住房的供给力度，**完善住房分配体系；**加强对房地产市场的监管，**规范市场秩序；**引导房地产行业转型升级，**提高发展质量。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.